Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above 200-Day Moving Average – Time to Sell?

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.35 and traded as high as $3.95. Cumberland Pharmaceuticals shares last traded at $3.88, with a volume of 122,573 shares traded.

Analysts Set New Price Targets

A number of research firms have recently commented on CPIX. Wall Street Zen upgraded shares of Cumberland Pharmaceuticals to a “hold” rating in a report on Saturday, January 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cumberland Pharmaceuticals has an average rating of “Sell”.

Cumberland Pharmaceuticals Price Performance

The firm has a fifty day moving average of $4.00 and a two-hundred day moving average of $3.35. The stock has a market capitalization of $58.04 million, a P/E ratio of -16.17 and a beta of -0.52. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.23 and a quick ratio of 1.11.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in Cumberland Pharmaceuticals in the second quarter worth approximately $34,000. Heron Bay Capital Management purchased a new position in shares of Cumberland Pharmaceuticals in the 2nd quarter valued at $111,000. Two Sigma Investments LP raised its position in shares of Cumberland Pharmaceuticals by 16.5% in the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after acquiring an additional 5,326 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Cumberland Pharmaceuticals during the 4th quarter worth $192,000. Finally, Geode Capital Management LLC lifted its stake in shares of Cumberland Pharmaceuticals by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock worth $427,000 after purchasing an additional 5,653 shares during the last quarter. 15.51% of the stock is owned by hedge funds and other institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.